Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear. METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), or to receive warfarin. Patients received the study drug for 3 to 12 months. The primary efficacy outcome was recurrent symptomatic venous thromboembolism. The principal safety outcome was major or clinically relevant nonmajor bleeding. RESULTS: A total of 4921 patients presented with deep-vein thrombosis, and 3319 with a pulmonary embolism. Among patients receiving warfarin, the time in the therapeutic range was 63.5%. Edoxaban was noninferior to warfarin with respect to the primary efficacy outcome, which occurred in 130 patients in the edoxaban group (3.2%) and 146 patients in the warfarin group (3.5%) (hazard ratio, 0.89; 95% confidence interval [CI], 0.70 to 1.13; P<0.001 for noninferiority). The safety outcome occurred in 349 patients (8.5%) in the edoxaban group and 423 patients (10.3%) in the warfarin group (hazard ratio, 0.81; 95% CI, 0.71 to 0.94; P=0.004 for superiority). The rates of other adverse events were similar in the two groups. A total of 938 patients with pulmonary embolism had right ventricular dysfunction, as assessed by measurement of N-terminal pro-brain natriuretic peptide levels; the rate of recurrent venous thromboembolism in this subgroup was 3.3% in the edoxaban group and 6.2% in the warfarin group (hazard ratio, 0.52; 95% CI, 0.28 to 0.98). CONCLUSIONS: Edoxaban administered once daily after initial treatment with heparin was noninferior to high-quality standard therapy and caused significantly less bleeding in a broad spectrum of patients with venous thromboembolism, including those with severe pulmonary embolism. (Funded by Daiichi-Sankyo; Hokusai-VTE ClinicalTrials.gov number, NCT00986154.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Self-citationDabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
The Epidemiology of Venous Thromboembolism
White, R. H. (2003) · Circulation · doi:10.1161/01.cir.0000078468.11849.66 · Cited by 2,310
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Pulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Cited by
Items 301–400 of 1,001
Sharifi, M., Bay, R. C., Schwartz, F. N., & Skrocki, L. (2013) · Clinical Cardiology · doi:10.1002/clc.22216 · Cited by 44
Antiphospholipid syndrome: an update
Merashli, M., Noureldine, M. H. A., Uthman, I. W., & Khamashta, M. A. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12449 · Cited by 47
Ageno, W., & Beyer‐Westendorf, J. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-06-0484 · Cited by 46
Gaertner, S., Cordeanu, E., Nouri, S., Faller, A., Frantz, A., Mirea, C., Bilbault, P., Ohlmann, P., Ray, I. L., & Stéphan, D. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.10.045 · Cited by 50
Current challenges and future prospects in oral anticoagulant therapy
Czuprynska, J., Patel, J. P., & Arya, R. (2017) · British Journal of Haematology · doi:10.1111/bjh.14714 · Cited by 45
“The DOAC VTE trials involved small numbers of patients with active cancer [5 2% of total patients in EINSTEIN (Prins et al, 2013), 3 1% in AMPLIFY (Agnelli et al, 2015) and 2 5% in HOKUSAI-VTE (Hokusai et al, 2013)].”
BackgroundAllison, T. A., Lin, P. J., Gass, J. A., Chong, K., Prater, S. J., Escobar, M. A., & Hartman, H. (2018) · Journal of Intensive Care Medicine · doi:10.1177/0885066618800657 · Cited by 44
“3) Admission scores, median (IQR) APACHE II score 20 (15-26) Glasgow coma score 15 (11-15) Required surgery, n (%) 6 (18.”
BackgroundGuidance on Short‐Term Management of Atrial Fibrillation in Coronavirus Disease 2019
Rattanawong, P., Shen, W. K., Masry, H. E., Sorajja, D., Srivathsan, K. S., Valverde, A. M., & Scott, L. R. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.017529 · Cited by 47
Managing pulmonary embolism from presentation to extended treatment
Cohen, A. T., Dobromirski, M., & Gurwith, M. M. P. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.09.040 · Cited by 49
Wu, C. M., Alotaibi, G., AlSaleh, K. A., Linkins, L., & McMurtry, M. S. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.10.033 · Cited by 43
Bertoletti, L., Ollier, É., Duvillard, C., Delavenne, X., Beyens, M., Magalhaes, É. D., Bellet, F., Basset, T., Mismetti, P., & Laporte, S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.06.023 · Cited by 50
A Practical Review of the Emerging Direct Anticoagulants, Laboratory Monitoring, and Reversal Agents
Joppa, S., Salciccioli, J. D., Adamski, J., Patel, S. I., Wysokiński, W. E., McBane, R. D., Al‐Saffar, F., Esser, H., & Shamoun, F. E. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7020029 · Cited by 49
“In a Phase II trial there was increased bleeding with higher doses of edoxaban as compared to warfarin [112].”
BackgroundKlok, F. A., Barco, S., Turpie, A. G. G., Haas, S. K., Kreutz, R. H., Mantovani, L. G., Gebel, M., Herpers, M., Bugge, J., Kostantinides, S. V., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15533 · Cited by 44
Yamashita, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., Toyofuku, M., et al. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.08.2206 · Cited by 43
Diagnosis and management of pulmonary embolism in the elderly
Robert‐Ebadi, H., & Righini, M. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.03.009 · Cited by 43
Kühn, J., Gripp, T., Flieder, T., Dittrich, M. T., Hendig, D., Busse, J., Knabbe, C., & Birschmann, I. (2015) · PLoS ONE · doi:10.1371/journal.pone.0145478 · Cited by 41
“Further direct oral anticoagulants, such as the DXaI endoxaban, will be released soon [2].”
BackgroundDirect Oral Anticoagulants in Cirrhosis
Intagliata, N. M., Maitland, H. S., & Caldwell, S. H. (2016) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-016-0092-0 · Cited by 42
Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment
Turpie, A. G. G., Purdham, D. M., & Ciaccia, A. (2017) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944717714921 · Cited by 44
Arthrocentesis and Joint Injection in Patients Receiving Direct Oral Anticoagulants
Yui, J. C., Preskill, C., & Greenlund, L. S. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.04.007 · Cited by 41
Progress in the monitoring of direct oral anticoagulant therapy
Patel, J. P., Byrne, R., Patel, R., & Arya, R. (2019) · British Journal of Haematology · doi:10.1111/bjh.15756 · Cited by 44
Patients with venous thromboembolism after spontaneous intracerebral hemorrhage: a review
Cai, Q., Zhang, X., & Chen, H. (2021) · Thrombosis Journal · doi:10.1186/s12959-021-00345-z · Cited by 44
“Buller [96] (2013) Randomized trial 4921 Edoxaban Warfarin 3.”
BackgroundEffective diagnosis and treatment of pulmonary embolism: Improving patient outcomes
Meyer, G. (2014) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2014.05.006 · Cited by 48
Alexander, P., Visagan, S., Issa, R., Gorantla, V. R., & Thomas, S. (2021) · Cureus · doi:10.7759/cureus.18992 · Cited by 46
Fang, M. C., Reynolds, K., Fan, D., Prasad, P. A., Sung, S. H., Portugal, C., Garcia, E. A., & Go, A. S. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.28033 · Cited by 49
Jannati, S., Patnaik, R., & Banerjee, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168727 · Cited by 47
Direct Oral Anticoagulants—Pharmacology, Drug Interactions, and Side Effects
Dempfle, C.-E. H. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.03.005 · Cited by 43
Mar, P. L., Familtsev, D., Ezekowitz, M. D., Lakkireddy, D., & Gopinathannair, R. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.09.035 · Cited by 43
New anticoagulants for the treatment of venous thromboembolism
Fernandes, C. J. C. D. S., Alves, J. L., Gavilanes, F., Prada, L. F., Morinaga, L. T. K., & Souza, R. (2016) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37562016042020068 · Cited by 70
“both analyzed in the aforementioned large-scale studies of new anticoagulants.(19-25) A recent meta-analysis(32)”
BackgroundMethodInfluentialBeenen, L. F. M., Bossuyt, P. M., Stoker, J., & Middeldorp, S. (2018) · European Respiratory Journal · doi:10.1183/13993003.02611-2017 · Cited by 40
Haas, S. K., Ageno, W., Weitz, J. I., Goldhaber, S. Z., Turpie, A. G. G., Goto, S., Angchaisuksiri, P., Nielsen, J. D., Kayani, G., Zaghdoun, A., et al. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14548 · Cited by 41
Guo, W., Chen, X., Tian, X., & Li, L. (2019) · Clinical Epidemiology · doi:10.2147/clep.s219335 · Cited by 41
Bleker, S. M., van Es, N., van Gils, L., Daams, J. G., Kleinjan, A., Buller, H. R., & Nisio, M. D. (2016) · Thrombosis Research · doi:10.1016/s0049-3848(16)30104-9 · Cited by 45
Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review
Sunkara, T., Ofori, E., Zarubin, V., Caughey, M. E., Gaduputi, V. V., & Reddy, M. (2016) · Health Services Insights · doi:10.4137/hsi.s40701 · Cited by 41
Kumano, O., Akatsuchi, K., & Amiral, J. (2021) · Biomedicines · doi:10.3390/biomedicines9030264 · Cited by 45
Anticoagulant use in older persons at risk for falls: therapeutic dilemmas—a clinical review
Mitchell, A., Elmasry, Y. E. T., van Poelgeest, E. P., & Welsh, T. J. (2023) · European Geriatric Medicine · doi:10.1007/s41999-023-00811-z · Cited by 44
Rivaroxaban for the treatment of venous thromboembolism
Aujesky, D., Beer, J. H., Mazzolai, L., Baldi, T., Banyai, M., Hayoz, D., Kaeslin, T., Korte, W. C., Escher, R., Husmann, M. J. W., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-03-0209 · Cited by 42
Drug interactions with new oral anticoagulants in elderly patients
Stöllberger, C. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1370369 · Cited by 47
“[1] Dabi RE-LY Man AF 18,113 40% 71 24 [2] Dabi RE-COVER I Man VTE 2,564 NR 54 6 [3] Dabi RE-COVER II Man VTE 2,589 NR 55 6 [4] Dabi RE-MEDY Man VTE 4,219 NR 55 16 [5] Apix ARISTOTLE Man AF 18,201 31% 70 22 [6] Apix AMPLIFY Man VTE 5,395 NR 57 6 [7] Riva ROCKET AF Man AF 14,264 38% 73 20 [8] Riva EINSTEIN DVT Man VTE…”
Yin, O. Q. P., Antman, E. M., Braunwald, E., Mercuri, M. F., Miller, R., Morrow, D. A., Ruff, C. T., Truitt, K. E., Weitz, J. I., & Giugliano, R. P. (2018) · Circulation · doi:10.1161/circulationaha.118.033933 · Cited by 39
Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban
Houghton, D. E., Casanegra, A. I., Peterson, L. G., Cochuyt, J. J., Hodge, D. O., Vlazny, D. T., McBane, R. D., Froehling, D. A., & Wysokiński, W. E. (2020) · American Journal of Hematology · doi:10.1002/ajh.25820 · Cited by 39
A review of indications and comorbidities in which warfarin may be the preferred oral anticoagulant
Wadsworth, D. C., Sullivan, E., Jacky, T., Sprague, T., Feinman, H., & Kim, J. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13343 · Cited by 42
Vitamin K Antagonists and Risk of Subdural Hematoma: Meta-Analysis of Randomized Clinical Trials
Connolly, B. J., Pearce, L. A., & Hart, R. G. (2014) · Stroke · doi:10.1161/strokeaha.114.005430 · Cited by 43
“†Safety population analysis excluded 28 randomized patients,(20) per-protocol analysis excluded 6 randomized patients,(21) and modified intention-to-treat analysis excluded 54 randomized patients.(23) Table 1.”
BackgroundPotential antidotes for reversal of old and new oral anticoagulants
Suryanarayan, D., & Schulman, S. (2014) · Thrombosis Research · doi:10.1016/s0049-3848(14)50026-6 · Cited by 42
How can we reverse bleeding in patients on direct oral anticoagulants?
Crowther, M. A., & Cuker, A. C. (2018) · Kardiologia Polska · doi:10.5603/kp.a2018.0197 · Cited by 43
Alhousani, M. M., Malik, S. U., Abu-Hashyeh, A., Poznanski, N. J., Al-Hasan, S., Roth, D. F., Alsharedi, M. F., & Mustafa, B. O. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.11.036 · Cited by 40
Cohen, A. T., Sah, J., Lee, T. T. H., Rosenblatt, L. C., Hlavacek, P., Emir, B., Keshishian, A. V., Yüce, H., & Luo, X. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10020200 · Cited by 42
Benz, A. P., Xu, L., Eikelboom, J. W., Middeldorp, S., Milling, T. J., Crowther, M. A., Yue, P., Conley, P. B., Lu, G., Connolly, S. J., et al. (2022) · Thrombosis and Haemostasis · doi:10.1055/s-0041-1740180 · Cited by 38
“6,7 12 The single-arm, international, prospective Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors (ANNEXA-4) study was designed to assess the efficacy and safety of andexanet in patients experiencing acute major bleeding on an oral factor Xa inhibitor or the…”
Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis.
Wang, K.-L., Chu, P. H., Lee, C., Pai, P. Y., Lin, P.-Y., Shyu, K. G., Chang, W., Chiu, K., Huang, C.-L., Lee, C. Y., et al. (2016) · Europe PMC (PubMed Central) · doi:10.6515/acs20151228a · Cited by 50
Reiffel, J. A., Weitz, J. I., Reilly, P. A., Kaminskas, E., Sarich, T. C., Sager, P. T., & Seltzer, J. H. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.04.010 · Cited by 38
Lippi, G., Ardissino, D., Quintavalla, R., & Cervellin, G. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-014-1082-5 · Cited by 38
Gómez‐Outes, A., Suárez‐Gea, M. L., Lecumberri, R., Terleira‐Fernández, A., & Vargas, E. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s50543 · Cited by 43
Sun, M. T., Wood, M. K., Chan, W. O., Selva, D. N., Sanders, P., Casson, R. J., & Wong, C. X. J. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2017.2199 · Cited by 46
Management of antithrombotic agents in patients undergoing flexible bronchoscopy
Abuqayyas, S., Raju, S., Bartholomew, J. R., Hweij, R. A., & Mehta, A. C. (2017) · European Respiratory Review · doi:10.1183/16000617.0001-2017 · Cited by 40
Venous Thromboembolism: Role of the Clinical Laboratory in Diagnosis and Management
Parakh, R. S., & Sabath, D. E. (2019) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2017.025734 · Cited by 40
The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis
Al-Samkari, H. T., & Connors, J. M. (2018) · Cancers · doi:10.3390/cancers10080271 · Cited by 41
“trials [29-33] demonstrating non-inferiority for preventing recurrent VTE.”
BackgroundResultUse of Direct Oral Anticoagulants in Morbidly Obese Patients
Kido, K., Lee, J. C., Hellwig, T. R., & Gulseth, M. P. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2353 · Cited by 38
Wang, X., Ma, Y., Xu, H., Li, M., Li, J., Tian, J., Wang, Q., Yan, P., Li, J., Xie, P., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010956.pub3 · Cited by 52
Панченко, Е. П., Balahonova, T. V., Danilov, N. M., Komarov, A. L., Станиславовна, К. Е., Saidova, M. A., Shakhmatova, O. O., & Yavelov, I. S. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-1-44-77 · Cited by 39
Sex‐specific differences in the presenting location of a first venous thromboembolism
Scheres, L. J. J., Brekelmans, M. P. A., Beenen, L. F. M., Buller, H. R., Cannegieter, S. C., & Middeldorp, S. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13712 · Cited by 40
Myeloid-related protein-14 regulates deep vein thrombosis
Wang, Y., Gao, H., Kessinger, C. W., Schmaier, A. H., Jaffer, F. A., & Simon, D. I. (2017) · JCI Insight · doi:10.1172/jci.insight.91356 · Cited by 41
Anticoagulantes orales directos: puesta al día
Franco‐Moreno, A., Díaz, R. M. M., & Navarro, M. J. G. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.11.042 · Cited by 39
Anticoagulation at the extremes of body weight: choices and dosing
McCaughan, G. J. B., Favaloro, E. J., Pasalic, L., & Curnow, J. L. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1517040 · Cited by 36
“Fifteen percent of patients in the Hokusai-VTE trial had a weight >100 kg and there was no difference in efficacy noted on subgroup analysis [94].”
BackgroundRecent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges
Frère, C., Benzidia, I., Marjanovic, Z., & Farge, D. (2019) · Cancers · doi:10.3390/cancers11010071 · Cited by 40
Rivaroxaban and the EINSTEIN clinical trial programme
Cohen, A. T., & Bauersachs, R. M. (2019) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000800 · Cited by 43
Updated recommendations for the treatment of venous thromboembolism
Hong, J., Ahn, S., Lee, Y. J., Lee, J. H., Han, J. W., Kim, K. H., Yhim, H., Nam, S., Kim, H., Song, J., et al. (2021) · Blood Research · doi:10.5045/br.2021.2020083 · Cited by 42
Jennings, I., Kitchen, D. P., Keeling, D. M., Fitzmaurice, D. A., & Heneghan, C. J. (2014) · British Journal of Haematology · doi:10.1111/bjh.13070 · Cited by 36
Yamashita, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., Toyofuku, M., et al. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.02.029 · Cited by 36
Caldeira, D., Canastro, M., Barra, M., Ferreira, A., Costa, J. N., Pinto, F. J., & Ferreira, J. J. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.0985 · Cited by 39
Therapy for Cancer-Related Thromboembolism
Frère, C., Debourdeau, P., Hij, A., Cajfinger, F., N'Guessan, M., Panicot‐Dubois, L., Dubois, C., & Farge, D. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.04.005 · Cited by 37
Cohen, A. T., Imfeld, S., & Rider, T. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0119-7 · Cited by 40
“The AMPLIFY and EINSTEIN trials excluded patients taking strong cytochrome P-450 inhibitors/inducers, which means that they should not be recommended for patients who require these agents [21, 22, 25, 26].”
BackgroundMethodResultInfluentialWho, when, and how to reverse non-vitamin K oral anticoagulants
Aronis, K. N., & Hylek, E. M. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1297-0 · Cited by 39
“8 % respectively [2–4, 10–13].”
BackgroundInfluentialYoshikawa, Y., Yamashita, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0229 · Cited by 37
Clinical Management of Pharmacokinetic Drug Interactions with Direct Oral Anticoagulants (DOACs)
Herink, M. C., Zhuo, Y. F., Williams, C. D., & DeLoughery, T. G. (2019) · Drugs · doi:10.1007/s40265-019-01183-0 · Cited by 35
Management of Outpatient Warfarin Therapy amid COVID-19 Pandemic: A Practical Guide
Kow, C. S., Sunter, W., Bain, A., Zaidi, S. T. R., & Hasan, S. S. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00415-z · Cited by 37
van Ommen, C. H., Albisetti, M., Chan, A. K. C., Estepp, J. H., Jaffray, J., Kenet, G., Young, G. A., Dave, J., GROSSO, M. A., & Duggal, A. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12352 · Cited by 35
Maughan, B. C., Frueh, L., McDonagh, M. S., Casciere, B., & Kline, J. A. (2020) · Academic Emergency Medicine · doi:10.1111/acem.14108 · Cited by 41
Biase, L. D., Lakkireddy, D. J., Marazzato, J., Velasco, A., Díaz, J. C., Navara, R., Chrispin, J., Rajagopalan, B., Natale, A., Mohanty, S., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.09.831 · Cited by 38
Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants
Wharin, C., & Tagalakis, V. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.11.001 · Cited by 36
“The Hokusai-VTE Investigators recently published results from their randomized, double-blind, noninferiority study comparing the oral factor Xa inhibitor, edoxaban, to warfarin for treatment of patients with acute VTE [31].”
MethodClemens, Fraessdorf, M., & Friedman, J. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s49830 · Cited by 35
Mismetti, P., Laporte, S., & Pellerin, O. (2015) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2015.11.006 · Cited by 38
Direct oral anticoagulants and venous thromboembolism
Franchini, M., & Mannucci, P. M. (2016) · European Respiratory Review · doi:10.1183/16000617.0025-2016 · Cited by 40
Lullo, L. D., Ronco, C., Cozzolino, M. G., Russo, D., Russo, L., Iorio, B. R. D., Pascalis, A. D., Bàrbera, V., Galliani, M., Vitaliano, E., et al. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.04.027 · Cited by 34
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations
Caterina, R. D., Ageno, W., Agnelli, G., Chan, N., Diener, H., Hylek, E. M., Raskob, G. E., Siegal, D. M., Verheugt, F. W. A., Lip, G. Y. H., et al. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1675816 · Cited by 37
Venous thromboembolism: A clinician update
Serhal, M., & Barnes, G. D. (2019) · Vascular Medicine · doi:10.1177/1358863x18821159 · Cited by 37
Fuentes, H. E., McBane, R. D., Wysokiński, W. E., Tafur, A. J., Loprinzi, C. L., Murad, M. H., & Riaz, I. B. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.05.035 · Cited by 41
Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE
Bounameaux, H., Haas, S. K., Farjat, A. E., Ageno, W., Weitz, J. I., Goldhaber, S. Z., Turpie, A. G. G., Goto, S., Angchaisuksiri, P., Nielsen, J. D., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.04.036 · Cited by 35
Pawar, A. M., Gagne, J. J., Gopalakrishnan, C., Iyer, G. S., Tesfaye, H., Brill, G. E., Chin, K., & Bykov, K. (2022) · JAMA · doi:10.1001/jama.2022.1920 · Cited by 34
Hillis, C., & Crowther, M. A. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-12-1036 · Cited by 36
Genge, L., Krala, A., Tritschler, T., Gal, G. L., Langlois, N., Dubois, S., West, C., Duffett, L. D., & Skeith, L. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15788 · Cited by 37
Lee, F. M. H., Chan, A. K. C., Lau, K. K., & Chan, H. H. W. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.01.031 · Cited by 37
Cancer-associated thrombosis: investigating the role of new oral anticoagulants
Franchini, M., Bonfanti, C., & Lippi, G. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.02.024 · Cited by 38
“The second meta-analysis by van der Hulle and colleagues identified 5 studies (RE-COVER [21], RE-COVER II [22], EINSTEIN-DVT [32], EINSTEIN-PE [33], Hokusai [30]) with 19060 patients, 973 (5.”
BackgroundInfluentialEfficacy and safety of novel anticoagulants in the elderly.
Karamichalakis, N., Georgopoulos, S., Vlachos, K. G., Liatakis, I., Efremidis, M., Sideris, A., & Letsas, Κ. P. (2016) · PubMed Central · doi:10.11909/j.issn.1671-5411.2016.08.011 · Cited by 40
Mai, V., Bertoletti, L., Cucherat, M., Mainbourg, S., Grangé, C., Provencher, S., & Lega, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214134 · Cited by 35
Netley, J., Howard, K., & Wilson, W. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01857-2 · Cited by 34
Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations
Elhosseiny, S., Moussawi, H. A., Chalhoub, J. M., Lafferty, J., & Deeb, L. S. (2019) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2019/4383269 · Cited by 33
Oh, H. J., Ryu, K. H., Park, B. J., & Yoon, B. (2021) · Medicine · doi:10.1097/md.0000000000025216 · Cited by 34
Brekelmans, M. P. A., Ageno, W., Beenen, L. F. M., Brenner, B., Buller, H. R., Chen, C. Z., Cohen, A. T., GROSSO, M. A., Meyer, G., Raskob, G. E., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30080-1 · Cited by 32
Pathogenesis, Diagnosis, and Treatment of Venous Thromboembolism in Older Adults
Johnson, S. A., Eleazer, G. P., & Rondina, M. T. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14279 · Cited by 35
Wille, K., Sadjadian, P., Becker, T. M., Kolatzki, V., Horstmann, A., Fuchs, C., & Grießhammer, M. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3483-6 · Cited by 34
Zakai, N. A., Walker, R. F., MacLehose, R. F., Adam, T. J., Alonso, Á., & Lutsey, P. L. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14303 · Cited by 33
Buijs, J. T., Laghmani, E. H., van den Akker, R. F. P., Tieken, C., Vletter, E. M., van der Molen, K., Crooijmans, J. J., Kroone, C., Dévédec, S. E. L., van der Pluijm, G., et al. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14443 · Cited by 34
Direct Anticoagulants and Risk of Myocardial Infarction, a Multiple Treatment Network Meta-Analysis
Kupó, P., Szakács, Z., Solymár, M., Habon, T., Czopf, L., Haţegan, L., Csányi, B., Borbás, J., Tringer, A., Varga, G., et al. (2019) · Angiology · doi:10.1177/0003319719874255 · Cited by 35
Metadata
- Authors
- The Hokusai-VTE Investigators
- Corresponding author
- The Hokusai-VTE Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-10
- Volume
- 369
- Issue
- 15
- Pages
- 1406-1415
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2160625453
- Cited by
- 1,869
- References
- 25
- Citations by year
- 2026: 52 · 2025: 75 · 2024: 112 · 2023: 104 · 2022: 116 · 2021: 128 · 2020: 179 · 2019: 170 · 2018: 190 · 2017: 173 · 2016: 210 · 2015: 173 · 2014: 161 · 2013: 25
- FWCI
- 165.78
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- IRIS (submittedVersion)
- Institutional Research Information System (Università degli Studi di Trento) (submittedVersion)
- Iris (University of Trento) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Daiichi-Sankyo
- LEO Pharma
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- warfarin, venous thromboembolism, factor Xa inhibitors, deep vein thrombosis, pulmonary embolism, recurrent venous thromboembolism, non-inferiority, bleeding risk, right ventricular dysfunction, N-terminal pro-brain natriuretic peptide, anticoagulation, heparin, renal dysfunction, body weight
- MeSH terms
- Aged, Anticoagulants, Double-Blind Method, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Pulmonary Embolism, Warfarin, Enoxaparin, Kaplan-Meier Estimate, Venous Thromboembolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.